Dr. Reddy's Laboratories Limited
NYSE:RDY · New York Stock Exchange
-$0.15 today
Vol 1.33M · Avg 2.39M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NYSE:RDY · Revenue to Net Income
Key Ratios
Analysis
$337.1B of revenue converted into $42.9B of net income for the selected period. Gross margin is 52.5% and net margin is 12.4%, showing how much revenue survives after costs and taxes. EPS is $51.47, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $353.5B +8.6% | $325.5B +16.6% | $279.2B +13.5% | $245.9B +14.7% | $214.4B | $1.0B | $809.6M | $921.6M |
| Cost of Revenue | $167.0B +23.6% | $135.1B +16.9% | $115.6B +8.5% | $106.5B +6.0% | $100.6B | $344.8M | $725.6M | $804.0M |
| Gross Profit | $186.5B -2.1% | $190.4B +16.4% | $163.6B +17.4% | $139.3B +22.4% | $113.8B | $10.3B | $8.9B | $7.6B |
| Gross Margin | 52.8% -5.7pp | 58.5% -0.1pp | 58.6% +1.9pp | 56.7% +3.6pp | 53.1% | 45.5% | 9.8% | 28.9% |
| Research & Development | $25.3B -7.5% | $27.4B +19.7% | $22.9B +18.0% | $19.4B +10.9% | $17.5B | $378.4M | $983.2M | $1.3B |
| Selling, General & Admin | $112.3B +19.7% | $93.9B +21.6% | $77.2B +13.5% | $68.0B +9.6% | $62.1B | $1.4B | $620.6M | $923.0M |
| Operating Expenses | $137.7B +16.1% | $118.6B +23.7% | $95.9B +16.6% | $82.2B -2.6% | $84.4B | $3.6B | $5.3B | $7.0B |
| Depreciation & Amortization | $21.7B +27.1% | $17.1B +14.9% | $14.8B +17.5% | $12.6B +6.9% | $11.8B | $1.2B | $374.2M | $1.2B |
| EBITDA | $83.3B -13.8% | $96.7B +9.3% | $88.4B +18.8% | $74.4B +65.1% | $45.1B | $12.6B | -$15.2B | $6.8B |
| EBITDA Margin | 23.6% -6.1pp | 29.7% -2.0pp | 31.7% +1.4pp | 30.3% +9.2pp | 21.0% | 10.0% | 5.6% | 46.3% |
| Operating Income | $48.9B -32.0% | $71.8B +6.1% | $67.7B +18.5% | $57.1B +93.9% | $29.5B | $10.6B | $12.3B | $14.0B |
| Operating Margin | 13.8% -8.2pp | 22.1% -2.2pp | 24.3% +1.0pp | 23.2% +9.5pp | 13.7% | 18.7% | 16.6% | 24.1% |
| Interest Income | $8.3B +209.3% | $2.7B +17.5% | $2.3B +93.1% | $1.2B +22.3% | $965.0M | $1.3B | -$1.5B | -$1.6B |
| Interest Expense | $3.9B +39.0% | $2.8B +65.3% | $1.7B +19.8% | $1.4B +49.1% | $958.0M | $969.2M | $1.1B | $1.0B |
| Other Income / Expenses | $8.8B +78.3% | $4.9B +19.3% | $4.1B +28.5% | $3.2B +14.2% | $2.8B | -$1.6B | -$1.5B | $1.4B |
| Income Before Tax | $57.7B -24.9% | $76.8B +6.8% | $71.9B +19.1% | $60.4B +86.9% | $32.3B | -$15.6B | $3.3B | $4.9B |
| Pre-Tax Margin | 16.3% -7.3pp | 23.6% -2.2pp | 25.7% +1.2pp | 24.6% +9.5pp | 15.1% | 13.3% | 20.8% | 18.7% |
| Income Tax Expense | $13.0B -33.5% | $19.5B +20.7% | $16.2B +5.8% | $15.3B +75.3% | $8.7B | $666.8M | $1.3B | -$1.6B |
| Net Income | $45.1B -20.3% | $56.5B +1.5% | $55.7B +23.6% | $45.1B +91.2% | $23.6B | $5.0B | $4.9B | $4.8B |
| Net Margin | 12.8% -4.6pp | 17.4% -2.6pp | 19.9% +1.6pp | 18.3% +7.3pp | 11.0% | 7.4% | 12.4% | 17.5% |
| EPS (Basic) | $54 -20.5% | $68 +1.6% | $67 +23.0% | $54 +91.0% | $28 | $1.2B | $400.8M | $703.2M |
| EPS (Diluted) | $54 -20.4% | $68 +1.5% | $67 +23.3% | $54 +91.1% | $28 | $620.6M | $766.2M | $609.4M |
| Weighted Avg Shares | $832.4M -0.1% | $833.3M -0.0% | $833.5M +0.4% | $830.2M +0.1% | $829.4M | $892.2M | $757.8M | $925.8M |
| Weighted Avg Shares (Diluted) | $833.3M -0.1% | $834.3M +0.1% | $833.5M +0.2% | $831.9M +0.0% | $831.7M | $319.6M | $1.2B | $924.4M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Revolution Medicines, Inc.
NASDAQ:RVMD
$33.54B
Viatris Inc.
NASDAQ:VTRS
$18.32B
Neurocrine Biosciences, Inc.
NASDAQ:NBIX
$15.99B
Exelixis, Inc.
NASDAQ:EXEL
$13.18B
Solventum Corporation
NYSE:SOLV
$12.91B
Elanco Animal Health Incorporated
NYSE:ELAN
$11.68B
Revvity, Inc.
NYSE:RVTY
$10.91B
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
$10.63B
Encompass Health Corporation
NYSE:EHC
$9.71B
The Ensign Group, Inc.
NASDAQ:ENSG
$9.11B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does RDY generate?
Dr. Reddy's Laboratories Limited (RDY) reported $353.47B of revenue in fiscal 2026.
Is RDY profitable?
Dr. Reddy's Laboratories Limited (RDY) reported $45.09B of net income, with a net margin of 12.8%.
Explore More
Continue the stock analysis
Jump to another research area for this company.